AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19900238 — intervention group
Group type: COMPARATOR
Intervention: Individual one-off appointments with a dietitian (Control group) (n = 155)
Number of subjects: 317
Study 17410097 — intervention group
Group type: EXPERIMENTAL
Intervention: sirolimus/mycophenolate mofetil/methylprednisolone (SRL)
Number of subjects: 24
Study 17410097 — intervention group
Group type: COMPARATOR
Intervention: cyclosporine with either mycophenolate mofetil or methylprednisolone (CsA)
Number of subjects: 24
Study 15675636 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle modification program
Number of subjects: 279
Study 15675636 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 279
Study 11176549 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual medical care plus clinical pharmacist interventions
Number of subjects: 1054
Study 11176549 — intervention group
Group type: COMPARATOR
Intervention: Usual medical care
Number of subjects: 1054
Study 9682118 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracameral injection of unpreserved lidocaine (0.5 cc of a 1% unpreserved solution)
Number of subjects: 100
Study 9682118 — intervention group
Group type: COMPARATOR
Intervention: Balanced salt solution (control)
Number of subjects: 100
Study 8018617 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramyometrial vasopressin (20 units diluted to 20 ml in normal saline)
Number of subjects: 20
Study 8018617 — intervention group
Group type: COMPARATOR
Intervention: Placebo (20 ml normal saline)
Number of subjects: 20
Study 29976228 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent screening and treatment with artemether-lumefantrine (ISTp-AL)
Number of subjects: 459
Study 28477959 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol B (novel contrast medium formula)
Number of subjects: 120
Study 26221889 — intervention group
Group type: EXPERIMENTAL
Intervention: Embolization + mecobalamin treatment
Number of subjects: 56
Study 26221889 — intervention group
Group type: COMPARATOR
Intervention: Embolization treatment
Number of subjects: 56
Study 24215148 — intervention group
Group type: EXPERIMENTAL
Intervention: Compassion focused therapy (CFT) plus treatment as usual (TAU)
Number of subjects: 40
Study 24215148 — intervention group
Group type: EXPERIMENTAL
Intervention: Compassion focused therapy (CFT)
Number of subjects: 40
Study 24215148 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 40
Study 21136070 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal acetaminophen (30 mg/kg)
Number of subjects: 110
Study 21136070 — intervention group
Group type: COMPARATOR
Intervention: Peritonsillar bupivacaine infiltration (1 mg/kg)
Number of subjects: 110
Study 21136070 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents' and nurses' satisfaction regarding patient analgesia
Number of subjects: 110
Study 18523108 — intervention group
Group type: EXPERIMENTAL
Intervention: Paraprofessional home visitation program (HVP) with four visits every two weeks focusing on injury prevention practices, home inspection, and supply of safety devices.
Number of subjects: 400
Study 18523108 — intervention group
Group type: EXPERIMENTAL
Intervention: Paraprofessional home visitation program (HVP)
Number of subjects: 400
Study 16740758 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Number of subjects: 643
Study 16740758 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 643
Study 12915284 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral training program for parents
Number of subjects: 242
Study 12915284 — intervention group
Group type: COMPARATOR
Intervention: Information-centered standard program
Number of subjects: 242
Study 12915284 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 242
Study 10693094 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (10 mg/kg loading dose followed by 5 mg/kg every 12 hours)
Number of subjects: 18
Study 10693094 — intervention group
Group type: COMPARATOR
Intervention: Control (conventional treatment)
Number of subjects: 18
Study 9339154 — intervention group
Group type: EXPERIMENTAL
Intervention: Supinator garment
Number of subjects: 10
Study 9339154 — intervention group
Group type: EXPERIMENTAL
Intervention: Pronator garment
Number of subjects: 10
Study 9339154 — intervention group
Group type: COMPARATOR
Intervention: Garments with no torsional force
Number of subjects: 10
Study 9339154 — intervention group
Group type: EXPERIMENTAL
Intervention: All garments
Number of subjects: 10
Study 8157041 — intervention group
Group type: EXPERIMENTAL
Intervention: Probenecid
Number of subjects: 0
Study 3818510 — intervention group
Group type: EXPERIMENTAL
Intervention: MDI plus Aerochamber
Number of subjects: 15
Study 3818510 — intervention group
Group type: EXPERIMENTAL
Intervention: Jet nebulizer
Number of subjects: 15
Study 29721510 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation group (≥42 patients)
Number of subjects: 63
Study 29721510 — intervention group
Group type: COMPARATOR
Intervention: Standard pharmacotherapy alone (≥21 patients)
Number of subjects: 63
Study 27918466 — intervention group
Group type: EXPERIMENTAL
Intervention: Dog safety website
Number of subjects: 69
Study 27918466 — intervention group
Group type: COMPARATOR
Intervention: Control transportation safety website
Number of subjects: 69
Study 24562087 — intervention group
Group type: EXPERIMENTAL
Intervention: DBT+DBT PE
Number of subjects: 26
Study 24562087 — intervention group
Group type: COMPARATOR
Intervention: DBT
Number of subjects: 26
Study 22593114 — intervention group
Group type: EXPERIMENTAL
Intervention: 50-Hz rTMS
Number of subjects: 26
Study 22593114 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 26
Study 20940522 — intervention group
Group type: EXPERIMENTAL
Intervention: Naftopidil 50mg once daily (Naf group)
Number of subjects: 68
Study 20940522 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin 0.2mg once daily (Tam group)
Number of subjects: 68
Study 20940522 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 68
Study 20940522 — intervention group
Group type: COMPARATOR
Intervention: Naf vs Tam
Number of subjects: 68
Study 18165400 — intervention group
Group type: EXPERIMENTAL
Intervention: Titrated oral misoprostol
Number of subjects: 207
Study 18165400 — intervention group
Group type: COMPARATOR
Intervention: Vaginal misoprostol
Number of subjects: 207
Study 15823909 — intervention group
Group type: EXPERIMENTAL
Intervention: UVB treatment guided by skin reflectance measurements
Number of subjects: 20
Study 15823909 — intervention group
Group type: COMPARATOR
Intervention: Conventional UVB regimen with fixed dosage increments
Number of subjects: 20
Study 11978674 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 6000
Study 11978674 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6000
Study 11978674 — intervention group
Group type: COMPARATOR
Intervention: Sulfonylurea, Metformin, or Insulin
Number of subjects: 6000
Study 10071153 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage 3 ROP
Number of subjects: 144
Study 10071153 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage 2 and 3 ROP
Number of subjects: 144
Study 10071153 — intervention group
Group type: COMPARATOR
Intervention: Healthy preterm infants (Control)
Number of subjects: 144
Study 7574132 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized dexamethasone (1.5 mg/kg)
Number of subjects: 111
Study 7574132 — intervention group
Group type: COMPARATOR
Intervention: Oral prednisone (2 mg/kg)
Number of subjects: 111
Study 2150736 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (300-1500 mg daily)
Number of subjects: 0
Study 2150736 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (160 mg daily)
Number of subjects: 0
Study 2150736 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of aspirin with streptokinase
Number of subjects: 0
Study 2150736 — intervention group
Group type: COMPARATOR
Intervention: Aspirin in healthy doctors (primary prevention trials)
Number of subjects: 0
Study 6771599 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid
Number of subjects: 58
Study 6771599 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 31880796 — intervention group
Group type: EXPERIMENTAL
Intervention: Lemborexant 5 mg
Number of subjects: 1006
Study 31880796 — intervention group
Group type: EXPERIMENTAL
Intervention: Lemborexant 10 mg
Number of subjects: 1006
Study 29525822 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor (180-mg loading dose, 90 mg twice daily thereafter)
Number of subjects: 3799
Study 29525822 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel (300-600 mg loading dose, 75 mg daily thereafter)
Number of subjects: 3799
Study 29525822 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 3799
Study 29525822 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 3799
Study 27093052 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint reminiscence groups (weekly for twelve weeks; monthly maintenance sessions for further seven months)
Number of subjects: 488
Study 27093052 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 488
Study 24091061 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed intervention providing instructions for taste exposure (14 daily tastes of a disliked vegetable with a sticker reward)
Number of subjects: 472
Study 24091061 — intervention group
Group type: COMPARATOR
Intervention: No treatment control condition
Number of subjects: 472
Study 21822913 — intervention group
Group type: EXPERIMENTAL
Intervention: Casopitant 90 mg IV added to ondansetron 8 mg bid oral and dexamethasone 8 mg IV
Number of subjects: 0
Study 21822913 — intervention group
Group type: COMPARATOR
Intervention: Placebo added to ondansetron 8 mg bid oral and dexamethasone 8 mg IV
Number of subjects: 0
Study 21822913 — intervention group
Group type: EXPERIMENTAL
Intervention: Casopitant 90 mg IV
Number of subjects: 0
Study 20934965 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (TIVA)
Number of subjects: 84
Study 18182866 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior program applied twice a week for 50 minutes per session over six weeks
Number of subjects: 40
Study 18182866 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40
Study 16235461 — intervention group
Group type: EXPERIMENTAL
Intervention: True ES (electrical stimulation) of ST36 and ST38 acupoints with nitroglycerin infusion
Number of subjects: 51
Study 16235461 — intervention group
Group type: COMPARATOR
Intervention: Sham ES of ST36 and ST38 acupoints with nitroglycerin infusion
Number of subjects: 51
Study 12198061 — intervention group
Group type: EXPERIMENTAL
Intervention: ropivacaine 0.1% 8 mL plus 75 microg of clonidine (Group 1)
Number of subjects: 66
Study 12198061 — intervention group
Group type: EXPERIMENTAL
Intervention: ropivacaine 0.2% 8 mL plus 75 microg of clonidine (Group 3)
Number of subjects: 66
Study 12198061 — intervention group
Group type: COMPARATOR
Intervention: ropivacaine 0.2% 8 mL plus 0.5 mL of NaCl 0.9% (Group 2)
Number of subjects: 66
Study 10450266 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate dose of alcohol before the second speech
Number of subjects: 40
Study 10450266 — intervention group
Group type: COMPARATOR
Intervention: Placebo alcoholic drink before both speeches
Number of subjects: 40
Study 8666102 — intervention group
Group type: EXPERIMENTAL
Intervention: ZIOS
Number of subjects: 21
Study 8666102 — intervention group
Group type: EXPERIMENTAL
Intervention: sRaw
Number of subjects: 21
Study 8666102 — intervention group
Group type: EXPERIMENTAL
Intervention: Ptc,O2
Number of subjects: 21
Study 8666102 — intervention group
Group type: EXPERIMENTAL
Intervention: Rint
Number of subjects: 21
Study 8666102 — intervention group
Group type: EXPERIMENTAL
Intervention: FEV1
Number of subjects: 21
Study 8666102 — intervention group
Group type: COMPARATOR
Intervention: Beta 2-agonist
Number of subjects: 21
Study 2135708 — intervention group
Group type: EXPERIMENTAL
Intervention: Propentofylline (3 x 300 mg)
Number of subjects: 190
Study 2135708 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3 x 1 tablet)
Number of subjects: 190
Study 2135708 — intervention group
Group type: EXPERIMENTAL
Intervention: Propentofylline (EEG brain mapping)
Number of subjects: 190
Study 2135708 — intervention group
Group type: COMPARATOR
Intervention: Placebo (EEG brain mapping)
Number of subjects: 190
Study 7358206 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone dipropionate
Number of subjects: 60
Study 7358206 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone acetate
Number of subjects: 60
Study 7358206 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone phosphate/acetate
Number of subjects: 60
Study 30290851 — intervention group
Group type: EXPERIMENTAL
Intervention: Information plus intervention group (receiving text messages with HIV prevention information and quiz questions with prize opportunities)
Number of subjects: 200
Study 30290851 — intervention group
Group type: COMPARATOR
Intervention: Information only control group (receiving text messages with HIV prevention information)
Number of subjects: 200
Study 27627654 — intervention group
Group type: EXPERIMENTAL
Intervention: AmBisome + SSG (10 mg/kg single dose AmBisome plus 10 days of SSG at 20 mg/kg/day)
Number of subjects: 51
Study 27627654 — intervention group
Group type: EXPERIMENTAL
Intervention: AmBisome + Miltefosine (10 mg/kg single dose AmBisome plus 10 days of miltefosine at 2.5 mg/kg/day)
Number of subjects: 51
Study 27627654 — intervention group
Group type: COMPARATOR
Intervention: Miltefosine alone (2.5 mg/kg/day for 28 days)
Number of subjects: 51
Study 24619855 — intervention group
Group type: EXPERIMENTAL
Intervention: Sub-Tenon block (ST)
Number of subjects: 67
Study 24619855 — intervention group
Group type: COMPARATOR
Intervention: Intravenous fentanyl (F)
Number of subjects: 67
Study 22119570 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative doxycycline treatment
Number of subjects: 13
Study 22119570 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical stabilisation
Number of subjects: 13
Study 22119570 — intervention group
Group type: COMPARATOR
Intervention: Control stifles of unaffected dogs
Number of subjects: 13
Study 19913346 — intervention group
Group type: EXPERIMENTAL
Intervention: ECC with device
Number of subjects: 93
Study 19913346 — intervention group
Group type: COMPARATOR
Intervention: ECC without device
Number of subjects: 93
Study 18274908 — intervention group
Group type: EXPERIMENTAL
Intervention: HBV video
Number of subjects: 328
Study 18274908 — intervention group
Group type: COMPARATOR
Intervention: Smoking prevention video
Number of subjects: 328
Study 16183787 — intervention group
Group type: EXPERIMENTAL
Intervention: Galactose-deficient IgG levels in serum and gingival crevicular fluid from periodontal disease patients
Number of subjects: 0
Study 16183787 — intervention group
Group type: EXPERIMENTAL
Intervention: Gingival tissue from periodontal disease patients
Number of subjects: 0
Study 16183787 — intervention group
Group type: EXPERIMENTAL
Intervention: IgG secreted by B-cells in periodontal disease patients
Number of subjects: 0
Study 12604870 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular exercise (n=24)
Number of subjects: 41
Study 12604870 — intervention group
Group type: COMPARATOR
Intervention: Non-exercisers (n=17)
Number of subjects: 41
Study 12604870 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular exercise
Number of subjects: 41
Study 10783345 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant follicle stimulating hormone (rFSH; follitropin alpha)
Number of subjects: 168
Study 10783345 — intervention group
Group type: COMPARATOR
Intervention: highly purified urinary FSH (uFSH; urofollitropin HP)
Number of subjects: 168
Study 8938163 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alpha2a (6 million units starting dose, titrated for 12 months)
Number of subjects: 234
Study 8938163 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alphaN1 (6 million units starting dose, titrated for 12 months)
Number of subjects: 234
Study 8938163 — intervention group
Group type: COMPARATOR
Intervention: IFN-alpha2a
Number of subjects: 234
Study 8938163 — intervention group
Group type: COMPARATOR
Intervention: IFN-alphaN1
Number of subjects: 234
Study 1612300 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon
Number of subjects: 136
Study 1612300 — intervention group
Group type: EXPERIMENTAL
Intervention: L-hyoscyamine
Number of subjects: 136
Study 1612300 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study 6428279 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen 1 mg p.o. q 12 h
Number of subjects: 17
Study 6428279 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 30617102 — intervention group
Group type: EXPERIMENTAL
Intervention: e-assist: Colon Health
Number of subjects: 0
Study 30617102 — intervention group
Group type: COMPARATOR
Intervention: Usual care plus
Number of subjects: 0
Study 30617102 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 30131303 — intervention group
Group type: EXPERIMENTAL
Intervention: Class 3 compression stockings (Tubulcus; Laboratoires Innothera, Arcueil, France)
Number of subjects: 361
Study 30131303 — intervention group
Group type: COMPARATOR
Intervention: Class 2 compression stockings (Rudo, Nis, Serbia)
Number of subjects: 361
Study 30131303 — intervention group
Group type: EXPERIMENTAL
Intervention: Class 3 compression stockings
Number of subjects: 361
Study 30131303 — intervention group
Group type: COMPARATOR
Intervention: Class 2 compression stockings
Number of subjects: 361
Study 26530475 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention
Number of subjects: 27
Study 25176015 — intervention group
Group type: EXPERIMENTAL
Intervention: LCZ696 (200 mg twice daily)
Number of subjects: 8442
Study 25176015 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (10 mg twice daily)
Number of subjects: 8442
Study 25176015 — intervention group
Group type: EXPERIMENTAL
Intervention: LCZ696
Number of subjects: 8442
Study 25176015 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 8442
Study 22770372 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (75mg/m2), pemetrexed (500mg/m2), and bevacizumab (15mg/kg) every 21 days for a maximum of 6 cycles.
Number of subjects: 52
Study 22770372 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (75mg/m2), pemetrexed (500mg/m2), and bevacizumab (15mg/kg) every 21 days until progression or intolerance.
Number of subjects: 52
Study 22770372 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin and pemetrexed alone (historical control).
Number of subjects: 52
Study 21098426 — intervention group
Group type: EXPERIMENTAL
Intervention: SmartDelay (electrogram-based algorithm)
Number of subjects: 1014
Study 21098426 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiography-optimized AV delay
Number of subjects: 1014
Study 21098426 — intervention group
Group type: COMPARATOR
Intervention: Fixed AV delay (120 milliseconds)
Number of subjects: 1014
Study 21098426 — intervention group
Group type: EXPERIMENTAL
Intervention: SmartDelay
Number of subjects: 1014
Study 21098426 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiography
Number of subjects: 1014
Study 18500047 — intervention group
Group type: EXPERIMENTAL
Intervention: F+OG
Number of subjects: 8
Study 18500047 — intervention group
Group type: EXPERIMENTAL
Intervention: 2PC(vent)
Number of subjects: 8
Study 18500047 — intervention group
Group type: COMPARATOR
Intervention: 1PC
Number of subjects: 8
Study 18500047 — intervention group
Group type: COMPARATOR
Intervention: 2PC
Number of subjects: 8
Study 15654172 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 10 mg/day and psychotherapy for 8 weeks
Number of subjects: 34
Study 15654172 — intervention group
Group type: COMPARATOR
Intervention: Control group (28 patients)
Number of subjects: 34
Study 12208593 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 160 mg q.d. (n=70)
Number of subjects: 141
Study 12208593 — intervention group
Group type: COMPARATOR
Intervention: Enalapril 10 mg b.i.d. (n=71)
Number of subjects: 141
Study 10599365 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphasalazine treatment
Number of subjects: 32
Study 8944992 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective cerebral perfusion (SCP)
Number of subjects: 20
Study 8944992 — intervention group
Group type: COMPARATOR
Intervention: Standard hypothermic cardiopulmonary bypass (Control)
Number of subjects: 20
Study 1901686 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin/clavulanate suspension (Spektramox) for 7 days
Number of subjects: 102
Study 1901686 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin suspension (Imacillin) for 10 days
Number of subjects: 102
Study 6846478 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist immobilization by a commercially available splint
Number of subjects: 18
Study 6846478 — intervention group
Group type: COMPARATOR
Intervention: Wrist free (control condition)
Number of subjects: 18
Study 31829245 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical‐TXA
Number of subjects: 207
Study 31829245 — intervention group
Group type: EXPERIMENTAL
Intervention: IV‐TXA
Number of subjects: 207
Study 31829245 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 207
Study 30032218 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized trials in nutrition
Number of subjects: 0
Study 30032218 — intervention group
Group type: EXPERIMENTAL
Intervention: Pivotal megatrials with tens of thousands of participants
Number of subjects: 0
Study 30032218 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct observation of participants in experimental in-house settings
Number of subjects: 0
Study 30032218 — intervention group
Group type: EXPERIMENTAL
Intervention: Registry-based designs and 'N-of-1' designs
Number of subjects: 0
Study 30032218 — intervention group
Group type: EXPERIMENTAL
Intervention: Mendelian randomization designs
Number of subjects: 0
Study 27031610 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity running three times a week (exercise intervention)
Number of subjects: 97
Study 27031610 — intervention group
Group type: COMPARATOR
Intervention: Wait list (no intervention)
Number of subjects: 97
Study 25041227 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-exposure everolimus (3–6 ng/mL) with reduced-exposure cyclosporine (n=56)
Number of subjects: 115
Study 25041227 — intervention group
Group type: COMPARATOR
Intervention: Standard-exposure cyclosporine (n=59)
Number of subjects: 115